Public company intelligence preview
CHEMED CORP
62 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $5.3M average total compensation across covered insiders.
Governance movement
Public aggregate: 1 governance events in the last year.
Institutional ownership
Public aggregate: 510 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Chemed Corp. is a diversified holding company in the Healthcare sector and Medical Care Facilities industry, with two main operating segments: VITAS, a major hospice and palliative care provider, and Roto-Rooter, a large plumbing, drain cleaning, and water restoration services business. The company’s operations are decentralized, while corporate management focuses on capital allocation, financial reporting, legal/tax matters, and leadership selection. Recent 10-Q data shows modest consolidated revenue growth driven by VITAS, while Roto-Rooter experienced softer demand in both residential and commercial activity. Chemed’s business mix creates a balance between a highly regulated, reimbursement-driven healthcare operation and a more cyclical, consumer-facing home services franchise.
Executive Compensation Practices
For Chemed, executive compensation is likely tied closely to a mix of earnings growth, adjusted EBITDA, cash flow generation, and capital allocation execution, since those metrics reflect the performance of both VITAS and Roto-Rooter. At VITAS, compensation incentives may be influenced by days of care growth, Medicare reimbursement rates, gross margin, and control of variable patient-care costs, because small changes in reimbursement or acuity mix can materially affect profitability. At Roto-Rooter, executives may be measured on revenue growth, pricing/mix improvement, advertising efficiency, and margin performance, especially given the competitive and fragmented nature of the home services market. The company’s continued share repurchases, acquisition activity, dividend policy, and debt management also suggest that long-term incentive plans may reward disciplined capital deployment rather than pure revenue expansion.
Insider Trading Considerations
Insider trading patterns at Chemed may be influenced by the company’s exposure to Medicare reimbursement timing, regulatory developments, and seasonal demand trends. Because VITAS revenue depends heavily on government reimbursement and billing cycles, insiders may be particularly attentive to quarterly care-day trends, cap pressures, and payment timing, which can create information advantages around results. Roto-Rooter’s performance can be affected by weather, advertising spend, and consumer demand, so insiders may trade around periods when seasonal or promotional trends become clearer. Given the healthcare regulatory environment, insiders may also face tighter practical trading windows around earnings, reimbursement updates, legal developments, and compliance issues tied to Medicare/Medicaid billing and other healthcare rules.
Unlock the full CHE insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.